NewLink Genetics Corp (NASDAQ:NLNK) insider has latelyjoinedan insider trading activity. Chairman of the Board and CEO, Link Charles J. Jr. sold 10,000 shares for $200,250 via through transaction Apr 07. Following the transaction, the insider now holds 282,756 shares in the company, priced at $3093350.64 as of Friday. Additional notable insider trading was performed by the same insider on Mar 15. Link Charles J. Jr. Sold 25,000 shares with $17.86 as the average price of common stock. That amounts to $446,600 in total. Apart from this, Langren Carl W. carried out a sale of 3,943 shares at $10.85 per share on Dec 14. The transaction was worth $42,782. Director Talarico Ernest III sold 4,065 shares for $50,081 via one transaction Jun 06. Following this sale, this insider’s ownership comprises 32,223 shares, priced at $352519.62 as of Friday.

The stock has seen a count of 1 insider trades in the past 3 months. These transactions include 1 sell trades and 0 buy activities. Furthermore, over the past 12 months, insider traded the stock on 16 occasions. In 10 instances, an employee was a seller while the insider of the company was the buyer in just 6 times.

NewLink Genetics Corp (NLNK) on November 1, 2016 reported consolidated financial results for the third quarter of 2016 and progress in its clinical and pipeline development programs.

“We continue to focus our clinical developmental efforts targeting the IDO pathway.  We have two distinct IDO pathway inhibitors advancing in the clinic, GDC-0919 with our partner Genentech and indoximod, our proprietary IDO pathway inhibitor,” said Charles J. Link, Jr. MD, Chairman, Chief Executive Officer and Chief Scientific Officer.  “We are also encouraged by recent clinical data that increasingly validate the IDO pathway as an important target in immuno-oncology.”

The Company hosted an investor day on October 25, outlining its vision and execution plans for the future.  A webcast of the Company’s presentations can be found at http://investors.linkp.com/events.cfm.

“As described at our investor day, we believe 2017 will be an important year in the development of both GDC-0919 and indoximod and we look forward to providing further updates and results,” added Nicholas N. Vahanian, MD, President and Chief Medical Officer.

The program featured leaders in the field of immuno-oncology and pioneers in the science of IDO:  George C. Prendergast, PhD, President & CEO, Lankenau Institute for Medical Research (LIMR) and Editor in Chief, Cancer Research; David H. Munn, MD, Professor of Pediatric Hematology-Oncology, Medical College of Georgia, Augusta University; Montaser Shaheen MD, Associate Professor, University of New Mexico Cancer Center; and Ashkan Emadi, MD, PhD, Associate Professor, University of Maryland.